Asterias Financial Statements From 2010 to 2022

Asterias Biotherapeutics financial statements provide useful quarterly and yearly information to potential Asterias Biotherapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Asterias Biotherapeutics financial statements helps investors assess Asterias Biotherapeutics' valuation, profitability, and current liquidity needs.
There are currently sixty-six fundamental signals for Asterias Biotherapeutics that can be evaluated and compared over time across rivals. Make sure you validate Asterias Biotherapeutics' prevailing fundamentals against the performance from 2010 to 2022 and make sure the trends continue to evolve in the right direction.
Asterias Biotherapeutics Tangible Asset Value is comparatively stable at the moment as compared to the past year. Asterias Biotherapeutics reported Tangible Asset Value of 41.55 Million in 2021. Working Capital is likely to gain to about 19 M in 2022, whereas Net Income Per Employee is likely to drop (888.7 K) in 2022.
  
Check Asterias Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Asterias main balance sheet or income statement drivers, such as Direct Expenses of 147.2 K, Cost of Revenue of 203.4 K or Gross Profit of 2.5 M, as well as many exotic indicators such as Long Term Debt to Equity of 4.0E-4, PPandE Turnover of 0.79 or Receivables Turnover of 6.03. Asterias financial statements analysis is a perfect complement when working with Asterias Biotherapeutics Valuation or Volatility modules. It can also supplement various Asterias Biotherapeutics Technical models . Check out Trending Equities.

Asterias Biotherapeutics Revenues

3.58 Million

Asterias Biotherapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets41.2 M38.8 M38.8 M
Increasing
Slightly volatile
Cash and Equivalents10.5 M11.9 M9.1 M
Increasing
Slightly volatile
Investments12.8 M15.7 M12.5 M
Increasing
Slightly volatile
Investments Current14.7 M15.3 M15.7 M
Increasing
Slightly volatile
Investments Non Current321.5 K374.4 K322.1 K
Increasing
Slightly volatile
Deferred Revenue2.2 M2.3 M2.5 M
Decreasing
Slightly volatile
Property Plant and Equipment Net5.6 M5.2 MM
Increasing
Slightly volatile
Tax Assets8.7 M8.8 M9.6 M
Decreasing
Slightly volatile
Trade and Non Trade Receivables492.4 K510.3 K529.6 K
Increasing
Slightly volatile
Trade and Non Trade Payables1.5 M1.5 M2.6 M
Decreasing
Slightly volatile
Goodwill and Intangible Assets25.4 M23.9 M22.4 M
Decreasing
Stable
Total Liabilities10.8 M8.6 M10.7 M
Increasing
Stable
Shareholders Equity30.4 M30.2 M28.2 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income421.4 K390.6 K69.3 K
Increasing
Slightly volatile
Current Assets21.8 M20.4 M20.7 M
Increasing
Slightly volatile
Assets Non Current26.7 M33.5 M26.1 M
Increasing
Slightly volatile
Current Liabilities4.2 MM5.1 M
Decreasing
Very volatile
Liabilities Non CurrentM10.5 M8.8 M
Increasing
Slightly volatile
Tax Liabilities10.4 M11.1 M10.9 M
Increasing
Slightly volatile
Total Debt29.5 K29.7 K32.5 K
Decreasing
Slightly volatile
Debt Current6.3 K6.3 K6.9 K
Decreasing
Slightly volatile
Debt Non Current23.3 K23.4 K25.6 K
Decreasing
Slightly volatile
Shareholders Equity USD43.8 M40.6 M31.1 M
Increasing
Slightly volatile
Cash and Equivalents USD10.9 M10.1 M7.3 M
Increasing
Slightly volatile
Total Debt USD29.5 K29.7 K32.5 K
Decreasing
Slightly volatile
Accounts Payable487 K360.9 K560 K
Decreasing
Slightly volatile
Receivables492.3 K510.3 K529.5 K
Increasing
Slightly volatile

Asterias Biotherapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues3.6 M3.6 M3.1 M
Increasing
Slightly volatile
Cost of Revenue203.4 K241.2 K194.4 K
Increasing
Slightly volatile
Selling General and Administrative Expense6.1 M7.1 M6.3 M
Increasing
Slightly volatile
Research and Development Expense12.8 M15.6 M12.7 M
Increasing
Slightly volatile
Operating Expenses18.9 M22.7 M19 M
Increasing
Slightly volatile
Interest Expense331.1 K306.9 K210.3 K
Increasing
Slightly volatile
Weighted Average Shares48.8 M45.2 M31.7 M
Increasing
Slightly volatile
Weighted Average Shares Diluted48.8 M45.2 M31.7 M
Increasing
Slightly volatile
Revenues USD2.7 M3.2 M2.6 M
Increasing
Slightly volatile
Gross Profit2.5 MM2.4 M
Increasing
Slightly volatile
Direct Expenses147.2 K148.5 K140.4 K
Increasing
Slightly volatile

Asterias Biotherapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and Disposals11.3 M11.4 M12.5 M
Decreasing
Slightly volatile
Net Cash Flow from Financing14.5 M15.5 M13.2 M
Increasing
Slightly volatile
Issuance Purchase of Equity Shares21.4 M19.9 M13.5 M
Increasing
Slightly volatile
Net Cash Flow from Investing1.1 M830.3 K486.2 K
Increasing
Stable
Net Cash Flow or Change in Cash and Cash Equivalents7.9 M7.3 M5.1 M
Increasing
Slightly volatile
Share Based Compensation3.5 M3.3 M2.6 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion2.8 M2.9 M2.8 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Gross Margin85.3286.3392.8725
Decreasing
Stable
Asset Turnover0.06520.06990.0551
Increasing
Slightly volatile
Sales per Share0.07840.07240.0719
Increasing
Slightly volatile
Price to Sales Ratio58.3144.7257.1097
Decreasing
Slightly volatile
Price to Book Value2.892.953.1419
Increasing
Very volatile
Debt to Equity Ratio6.0E-46.0E-40.0048
Decreasing
Slightly volatile
Current Ratio6.275.814.0376
Increasing
Slightly volatile
Book Value per Share1.161.07(22.0164)
Increasing
Slightly volatile
Tangible Assets Book Value per Share1.441.49.1431
Decreasing
Slightly volatile
Total Assets Per Share1.250.920.9762
Increasing
Stable
Receivables Turnover6.036.076.6341
Decreasing
Slightly volatile
PPandE Turnover0.790.730.8604
Decreasing
Stable
Cash and Equivalents Turnover0.390.280.3792
Decreasing
Slightly volatile
Accounts Payable Turnover4.684.934.1017
Increasing
Slightly volatile
Accrued Expenses Turnover1.431.441.5749
Decreasing
Slightly volatile
Long Term Debt to Equity4.0E-44.0E-40.0047
Decreasing
Slightly volatile
Quick Ratio3.183.562.9602
Increasing
Slightly volatile
Net Current Assets as percentage of Total Assets43.2540.09(4.3 K)
Increasing
Slightly volatile
Revenue to Assets0.07480.08440.0647
Increasing
Slightly volatile

Asterias Biotherapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization122.3 M133.1 M126.4 M
Increasing
Slightly volatile
Enterprise Value112.6 M121.8 M117 M
Increasing
Slightly volatile
Average Equity37.4 M38.8 M40.1 M
Increasing
Slightly volatile
Average Assets52.2 M52.7 M57.3 M
Decreasing
Slightly volatile
Invested Capital Average14 M14.1 M15.3 M
Decreasing
Stable
Tangible Asset Value44.8 M41.5 M31.5 M
Increasing
Slightly volatile
Working Capital19 M17.6 M12.1 M
Increasing
Slightly volatile
Revenue Per Employee103.1 K117.3 K92.3 K
Increasing
Slightly volatile

Asterias Fundamental Market Drivers

Average Daily Volume In Three Month13.94k
Fifty Day Average56.5550
Two Hundred Day Average46,394.2539

Asterias Upcoming Events

Upcoming Quarterly Report4th of April 2017
Next Financial Report15th of May 2017
Next Fiscal Quarter End31st of December 2016
Next Fiscal Year End4th of April 2017
Last Quarter Report30th of September 2016
Last Financial Announcement31st of December 2015

Be your own money manager

Our tools can tell you how much better you can do entering a position in Asterias Biotherapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Technical Analysis Now

   

Technical Analysis

Check basic technical indicators and analysis based on most latest market data
All  Next Launch Module

Pair Trading with Asterias Biotherapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Asterias Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Asterias Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Twitter could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Twitter when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Twitter - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Twitter to buy it.
The correlation of Twitter is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Twitter moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Twitter moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Twitter can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities. Note that the Asterias Biotherapeutics information on this page should be used as a complementary analysis to other Asterias Biotherapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Tools for Asterias Stock

When running Asterias Biotherapeutics price analysis, check to measure Asterias Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Asterias Biotherapeutics is operating at the current time. Most of Asterias Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Asterias Biotherapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Asterias Biotherapeutics' price. Additionally, you may evaluate how the addition of Asterias Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go